[go: up one dir, main page]

TR200200804T2 - Polimorfik tuz - Google Patents

Polimorfik tuz

Info

Publication number
TR200200804T2
TR200200804T2 TR2002/00804T TR200200804T TR200200804T2 TR 200200804 T2 TR200200804 T2 TR 200200804T2 TR 2002/00804 T TR2002/00804 T TR 2002/00804T TR 200200804 T TR200200804 T TR 200200804T TR 200200804 T2 TR200200804 T2 TR 200200804T2
Authority
TR
Turkey
Prior art keywords
polymorphic salt
virgin
migraine
agonist
receptors
Prior art date
Application number
TR2002/00804T
Other languages
English (en)
Inventor
Bentley Arthur
Arnold Howard-Field Simon
James Ogilvie Ronald
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of TR200200804T2 publication Critical patent/TR200200804T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bu bulus, 9.28, 10.38, 11.37, 12.40, 16.84, 17.46, 17.53, 17.78, 17.98, 19.48, 20.70, 21.29, 21.45, 22.21, 22.64, 23.08, 25.20 ve 25.79 noktalarinda ana pikler yapan, bakir K-alfa1 radyasyona (gamma=0.15046 nm) kullanilarak uygulanan bir toz X-isin ayristirma özelligi ile karakterize edilen bir formül (I) bilesiginin kristal yapida bir polimorfik formu ile ilgilidir. Bu bulus ayrica, sözü edilen formun hazirlanmasinda kullanilan islemlerle, bu formu içeren farmasötik bilesimlerle ve bu formun, tipta kullanimi, özellikle 5HT1 reseptörlerinin bir agonistinin endike oldugu tibbi durumlarin, söz gelimi migrenin tedavisinde kullanimi ile ilgilidir.
TR2002/00804T 1999-09-28 2000-09-14 Polimorfik tuz TR200200804T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9922963.5A GB9922963D0 (en) 1999-09-28 1999-09-28 Polymorphic salt

Publications (1)

Publication Number Publication Date
TR200200804T2 true TR200200804T2 (tr) 2002-07-22

Family

ID=10861767

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00804T TR200200804T2 (tr) 1999-09-28 2000-09-14 Polimorfik tuz

Country Status (50)

Country Link
US (1) US6369094B1 (tr)
EP (1) EP1233960B1 (tr)
JP (1) JP3795395B2 (tr)
KR (1) KR100479897B1 (tr)
CN (1) CN1155594C (tr)
AP (1) AP2004A (tr)
AR (1) AR025779A1 (tr)
AT (1) ATE246185T1 (tr)
AU (1) AU779580B2 (tr)
BG (1) BG65161B1 (tr)
BR (1) BR0014272A (tr)
CA (1) CA2379572C (tr)
CO (1) CO5180567A1 (tr)
CR (1) CR6561A (tr)
CU (1) CU23200A3 (tr)
CZ (1) CZ2002971A3 (tr)
DE (1) DE60004262T2 (tr)
DK (1) DK1233960T3 (tr)
DZ (1) DZ3254A1 (tr)
EA (1) EA004510B1 (tr)
EE (1) EE200200171A (tr)
EG (1) EG24143A (tr)
ES (1) ES2200911T3 (tr)
GB (1) GB9922963D0 (tr)
GE (1) GEP20043365B (tr)
GT (1) GT200000159A (tr)
HK (1) HK1048628B (tr)
HR (1) HRP20020270B1 (tr)
HU (1) HUP0202821A3 (tr)
IL (1) IL147154A (tr)
IS (1) IS2162B (tr)
MA (1) MA26821A1 (tr)
MX (1) MXPA02003311A (tr)
MY (1) MY121170A (tr)
NO (1) NO321936B1 (tr)
NZ (1) NZ516093A (tr)
OA (1) OA12024A (tr)
PA (1) PA8498901A1 (tr)
PE (1) PE20010662A1 (tr)
PL (1) PL354960A1 (tr)
PT (1) PT1233960E (tr)
SI (1) SI1233960T1 (tr)
SK (1) SK3982002A3 (tr)
TN (1) TNSN00187A1 (tr)
TR (1) TR200200804T2 (tr)
TW (1) TWI265926B (tr)
UA (1) UA72272C2 (tr)
WO (1) WO2001023377A2 (tr)
YU (1) YU2602A (tr)
ZA (1) ZA200202406B (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US20060025387A1 (en) * 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
EP3165220B2 (en) * 2004-12-03 2024-11-13 Merck Sharp & Dohme LLC Pharmaceutical composition containing an anti-nucleating agent
EP1951702A2 (en) * 2005-10-17 2008-08-06 NeuroTherapeutics Pharma, Inc. Diuretic-like compound analogs useful for regulation of central nervous system disorders
KR100814109B1 (ko) * 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
TWI394753B (zh) * 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
PL2493312T3 (pl) 2009-10-26 2022-01-03 Merck Sharp & Dohme Corp. Kompozycje farmaceutyczne w postaci ciała stałego zawierające inhibitor integrazy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
JP2575272B2 (ja) * 1990-10-15 1997-01-22 フアイザー・インコーポレイテツド インドール誘導体
US5559246A (en) 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
ID24528A (id) * 1997-07-03 2000-07-20 Pfizer Komposisi-komposisi obat farmasi yang mengandung eletriptan hemisulfat dan kafein

Also Published As

Publication number Publication date
BR0014272A (pt) 2002-05-21
EA200200302A1 (ru) 2002-10-31
ES2200911T3 (es) 2004-03-16
BG65161B1 (bg) 2007-04-30
ATE246185T1 (de) 2003-08-15
JP3795395B2 (ja) 2006-07-12
IS6223A (is) 2002-01-08
MXPA02003311A (es) 2002-10-04
OA12024A (en) 2006-04-19
HUP0202821A2 (hu) 2003-01-28
NZ516093A (en) 2005-01-28
IS2162B (is) 2006-11-15
KR20020032627A (ko) 2002-05-03
WO2001023377A3 (en) 2002-03-07
EG24143A (en) 2008-08-06
HK1048628B (zh) 2004-10-21
CA2379572C (en) 2006-11-14
HRP20020270B1 (en) 2004-04-30
IL147154A0 (en) 2002-08-14
CA2379572A1 (en) 2001-04-05
CN1364166A (zh) 2002-08-14
AP2004A (en) 2009-06-10
EP1233960A2 (en) 2002-08-28
NO321936B1 (no) 2006-07-24
TNSN00187A1 (fr) 2005-11-10
CR6561A (es) 2005-04-04
SI1233960T1 (en) 2003-12-31
CZ2002971A3 (cs) 2003-04-16
GB9922963D0 (en) 1999-12-01
NO20021525D0 (no) 2002-03-26
AU779580B2 (en) 2005-01-27
UA72272C2 (uk) 2005-02-15
DE60004262D1 (de) 2003-09-04
PE20010662A1 (es) 2001-06-23
WO2001023377A2 (en) 2001-04-05
EE200200171A (et) 2003-06-16
EA004510B1 (ru) 2004-04-29
WO2001023377A9 (en) 2002-03-28
HRP20020270A2 (en) 2003-06-30
MA26821A1 (fr) 2004-12-20
IL147154A (en) 2005-11-20
JP2003510318A (ja) 2003-03-18
CO5180567A1 (es) 2002-07-30
NO20021525L (no) 2002-03-26
DE60004262T2 (de) 2004-01-22
CU23200A3 (es) 2007-04-06
BG106240A (en) 2002-07-31
AR025779A1 (es) 2002-12-11
SK3982002A3 (en) 2003-05-02
TWI265926B (en) 2006-11-11
PT1233960E (pt) 2003-11-28
CN1155594C (zh) 2004-06-30
GEP20043365B (en) 2004-05-10
ZA200202406B (en) 2003-05-28
DK1233960T3 (da) 2003-10-27
AU6721300A (en) 2001-04-30
EP1233960B1 (en) 2003-07-30
DZ3254A1 (fr) 2001-04-05
YU2602A (sh) 2004-11-25
HK1048628A1 (en) 2003-04-11
PL354960A1 (en) 2004-03-22
PA8498901A1 (es) 2004-02-07
KR100479897B1 (ko) 2005-03-31
US6369094B1 (en) 2002-04-09
GT200000159A (es) 2002-03-20
AP2002002457A0 (en) 2002-06-30
HUP0202821A3 (en) 2003-12-29
MY121170A (en) 2005-12-30

Similar Documents

Publication Publication Date Title
TR200200804T2 (tr) Polimorfik tuz
BR9303993A (pt) Composto, processo para preparar o mesmo e composição farmacêutica
KR930019637A (ko) 비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도
DE69011318D1 (de) Diazinderivate als Angiotensin II Rezeptor Antagonisten.
EE200100558A (et) Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
HRP20060361A8 (en) Novel c-crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same
SE8406200D0 (sv) Indolderivat
RU94040390A (ru) Производные виниленазаиндола, способ их получения, фармацевтическая композиция
CY1109490T1 (el) Τρικυκλικοι τροποποιητες πυρηνικων υποδοχεων στεροειδων ορμονων
NO20030051L (no) Ny <gamma>-krystallinsk form av perindopril tert- butylaminsalt, fremgangsmåte for dens fremstilling og farmasöytiske sammensetningerinneholdende den
RU93054537A (ru) Производные гуанидиналкил-1,1-бисфосфоновой кислоты, способ их получения и их применение
ATE89547T1 (de) Dopamin-vorlaeufer.
RU92004509A (ru) Замещенные фенилфенольные соединения, фармацевтическая композиция, способ получения
CY1107753T1 (el) 2,5-δισυποκατεστημενο 3-μερκαπτοπεντανοϊκο οξυ
FI942882A (fi) Substituoituja imidatsolijohdannaisia ja niiden valmistus ja käyttö
DK602283A (da) Diethylaminoalkoxybenzhydrolderivater
RU2205829C2 (ru) Замещенное производное циклобутиламина, антибактериальный агент и фармацевтическая композиция на его основе
ATE14431T1 (de) Benzodioxin derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
KR930021638A (ko) 이미다조피리딘
ES8103081A1 (es) Procedimiento para la obtencion de diazatriciclos
EA200101180A1 (ru) Производные тио-оксиндола
IL71068A0 (en) N-arylpiperazine derivative,its preparation and pharmaceutical compositions containing it
DK601783D0 (da) Resorcinderivater
PE20010216A1 (es) Procedimiento para preparar derivados de 10,11-metanobenzosuberano
NO177707C (no) Fremgangsmåte for fremstilling av derivater av 2-(3-pyridyl)-2-tetrahydrotiopyrankarbotioamid-1-oksyd-(1R,2R)